Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06551142 · ClinicalTrials.gov registry record · Phase 1
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
A Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 590
- Enrollment target
- 20
- Study locations
NCT06551142: Recruiting Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.
NCT06551142 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 590 participants, below the 1,618-participant average among 158 other Neoplasms trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06551142, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 590 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- BIOLOGICAL Atezolizumab
- DRUG Cisplatin
- BIOLOGICAL GSK5764227
Study Locations (20)
Texas
- GSK Investigational Site - Austin
- GSK Investigational Site - Dallas
- GSK Investigational Site - San Antonio
- GSK Investigational Site - Tyler
Other
- GSK Investigational Site - Rosario
- GSK Investigational Site - Viedma
Ontario
- GSK Investigational Site - Ottawa
- GSK Investigational Site - Toronto
Quebec
- GSK Investigational Site - Montreal
- GSK Investigational Site - Sherbrooke
California
- GSK Investigational Site - Stanford
Colorado
- GSK Investigational Site - Denver
Connecticut
- GSK Investigational Site - New Haven
Massachusetts
- GSK Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-05-19 |
| Phase | Phase 1 |
What NCT06551142 shows while recruiting
NCT06551142 is an interventional study that assigns participants to a tested intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, below the 1,618-participant average among 158 other Neoplasms trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06551142 names 20 study sites across 14 states, led by Texas, Other, Ontario.
Frequently Asked Questions
What is clinical trial NCT06551142 about?
NCT06551142 is a clinical study titled "A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)". The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, c...
What is the current status of trial NCT06551142?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 590 participants. The study started on 2024-09-30. Estimated completion is 2027-05-19.
What conditions does trial NCT06551142 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT06551142?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Atezolizumab (BIOLOGICAL), Cisplatin (DRUG), GSK5764227 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06551142?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06551142 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06551142's enrollment target sits among peer trials
590 22nd of 158 higher than 137 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI